N-(γ-Aminopropyl)-2-methyl-5-ethyl-piperidin | 16140-56-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(γ-Aminopropyl)-2-methyl-5-ethyl-piperidin
• 英文别名: 3-(5-ethyl-2-methyl-piperidin-1-yl)-propylamine；3-(5-Ethyl-2-methyl-1-piperidinyl)-1-propanamine；3-(5-ethyl-2-methylpiperidin-1-yl)propan-1-amine
• CAS: 16140-56-0
• 化学式: C₁₁H₂₄N₂
• 分子量: 184.325
• InChiKey: QYXCDNMLYSGHSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Basic acyl amides of (5-amino-1,3-dialkylpyrazol-4-yl)(aryl)methanones, processes for their production, and pharmaceutical compositions containing such compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0068806A2

  公开（公告）日：1983-01-05

  Basic acylamides of (5-amino-1,3-dialkylpyrazol-4-yl)-(aryl)methanones and their pharmaceutically acceptable salts are provided, which have the formula: where the radicals are as defined in the specification. These compounds are useful for treating psychoses. Also provided are processes for preparing the compounds of the invention, and pharmaceutical compositions containing these compounds.

  本发明提供了(5-氨基-1,3-二烷基吡唑-4-基)-(芳基)甲酮的碱性酰酰胺及其药学上可接受的盐，其式为： 其中基团如说明书中所定义。 这些化合物可用于治疗精神病。 还提供了制备本发明化合物的工艺和含有这些化合物的药物组合物。
• IONIZABLE LIPIDOIDS AND THEIR USES
  申请人：Massachusetts Institute of Technology

  公开号：EP3844154A1

  公开（公告）日：2021-07-07
• [EN] IONIZABLE LIPIDOIDS AND THEIR USES<br/>[FR] LIPIDOÏDES IONISABLES ET LEURS UTILISATIONS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2020047399A1

  公开（公告）日：2020-03-05

  Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.